Different studies showed that the presence of MET activation in MET-mutant SCLC cell lines was predictive of poor outcome and the use of PHA-665752, a selective c-MET inhibitor, inhibited colony formation and invasiveness [47]. Here, MET is linked to small cell lung carcinoma.